Viewing Study NCT00295932


Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2025-12-25 @ 7:25 PM
Study NCT ID: NCT00295932
Status: COMPLETED
Last Update Posted: 2018-11-20
First Post: 2006-02-23
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE1 View
None PHASE2 View
Observational Models:
Time Perspective List:
Who Masked List: